Skip to Main Content U.S. Department of Energy
small banner

Next Generation Clinical Proteomics to Target Human Health Challenges

Richard Smith, Principal Investigator

Funding Agency: Life Sciences Discovery Fund

Focus: To develop a new proteomics (the large-scale identification of all the proteins in a sample, e.g., blood) technology and apply it in search of blood biomarkers for liver disease and in subsequent use as a powerful tool in the study of cancer, diabetes, and other conditions.

The investigators will develop and apply new technology to find blood proteins that reveal the earliest signs of chronic liver disease. The goal is to establish a safer, non-invasive, easier diagnostic process for liver fibrosis than liver biopsy, allowing an earlier intervention at lower cost and reduced levels of illness and patient discomfort. In Washington State, more than 4,000 people are diagnosed annually with liver disease caused by hepatitis C virus (HCV). About half are cured with a cost of $13 million for diagnosis. This team's technology platform would enable earlier diagnosis of HCV and is projected to increase successful treatment rates by nearly ten percent. Integral to this program is the extension of the technology platform to address problems in other diseases and to make it commercially available for broad clinical use.

Information regarding the Next Generation Clinical Proteomics to Target Human Health Challenges project was obtained from its Life Sciences Discovery Fund project page.

Systems Biology at PNNL

Research & Capabilities


Related Projects

Biomolecular Systems Initiative, image